With botanical claims temporarily extracted from the EU nutrition and health claims regulation (NHCR) assessment process there has been conjecture about how to treat botanical products.
Can tradition-of-use data be applied to herbal products, when it has been discounted in other nutrient areas?
Should all botanicals be assessed via the Traditional Herbal Medicinal Products Directive (THMPD)? What of those, like garlic extracts, that are used in cooking?
Kicking the event off, Penny Viner, vice president at the UK-based Health Food Manufacturers’ Association (HFMA) will posit the question: “Is the future for botanicals in the food law?”
Veteran EU law expert, Jean Savigny, senior partner at Keller and Hackman, will assess the impact of the ambiguity on businesses and competition.
Patrick Coppens, secretary general at the European Botanical Forum, will present a situation analysis across foods, botanicals and herbal medicines.
Dr Barbara Klaus, from Meyer’s Milan office in Italy, will discuss whether traditional knowledge or clinical data is most appropriate to support botanical claims. She will also highlight Italian and Belgian approaches to herbal products as examples that could be followed across the EU.
The increasingly scrutinised medical devices route will be explored Dr Ina Gerstberger, from Wragge and Co in Germany.
Other speakers include Dr Joerg Gruenwald, from German CRO, analyze & realize; Emmanuel Saurat from Sidley Austin in Belgium; Sebastian Romero Melchor from K&L Gates also in Belgium and author Bert Schwitters.
Further information can be found here.